Wen-chao Wang

发表

Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2019, Journal of medicinal chemistry.

Moderate and strong static magnetic fields directly affect EGFR kinase domain orientation to inhibit cancer cell proliferation

Qingsong Liu, Guohui Li, Q. Lu, 2016, Oncotarget.

STK16 regulates actin dynamics to control Golgi organization and cell cycle

Qingsong Liu, Xingxing Yang, Wen-chao Wang, 2017, Scientific Reports.

Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations

Q. Liu, Cheng Chen, Li Wang, 2022, Analytical cellular pathology.

Activated ALK collaborates with MYCN in neuroblastoma pathogenesis.

D. Neuberg, A. Look, J. Kutok, 2012, Cancer cell.

Discovery of 2-((3-Acrylamido-4-methylphenyl)amino)-N-(2-methyl-5-(3,4,5-trimethoxybenzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-BMX-078) as a Highly Potent and Selective Type II Irreversible Bone Marrow Kinase in the X Chromosome (BMX) Kinase Inhibitor.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2017, Journal of medicinal chemistry.

Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.

N. Gray, Qingsong Liu, W. Hur, 2017, European journal of medicinal chemistry.

Selectively targeting FLT3-ITD mutants over FLT3- wt by a novel inhibitor for acute myeloid leukemia

Qingsong Liu, E. Weisberg, Xiaofei Liang, 2020, Haematologica.

G protein γ subunit 7 induces autophagy and inhibits cell division

Xingxing Yang, Zhiyuan Li, Wen-chao Wang, 2016, Oncotarget.

Heat shock proteins: Biological functions, pathological roles, and therapeutic opportunities

Qingsong Liu, Hong Wu, Beilei Wang, 2022, MedComm.

Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.

Qingsong Liu, X. Liu, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Discovery of a Potent, Covalent BTK Inhibitor for B-Cell Lymphoma

N. Gray, Qingsong Liu, D. McMillin, 2014, ACS chemical biology.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Distinct Neuroblastoma-associated Alterations of PHOX2B Impair Sympathetic Neuronal Differentiation in Zebrafish Models

B. Paw, R. George, Wen-chao Wang, 2013, PLoS genetics.

Discovery of IHMT-MST1-58 as a Novel, Potent, and Selective MST1 Inhibitor for the Treatment of Type 1/2 Diabetes.

Q. Liu, Ao-li Wang, F. Zou, 2022, Journal of medicinal chemistry.

Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).

Qingsong Liu, Zhenquan Hu, Cheng Chen, 2021, European journal of pharmacology.

Ammonia Induces Autophagy through Dopamine Receptor D3 and MTOR

Qingsong Liu, Xiaofei Liang, U. Eggert, 2016, PloS one.

Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.

Qingsong Liu, C. Yun, Zhenquan Hu, 2018, European journal of medicinal chemistry.

Repurposing of the FGFR inhibitor AZD4547 as a potent inhibitor of necroptosis by selectively targeting RIPK1

Q. Liu, Juan Liu, Ao-li Wang, 2022, Acta Pharmacologica Sinica.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Hong Wu, C. Niu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Discovery of N-(5-((5-chloro-4-((2-(isopropylsulfonyl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(4-methyl-1,4-diazepan-1-yl)phenyl)acrylamide (CHMFL-ALK/EGFR-050) as a potent ALK/EGFR dual kinase inhibitor capable of overcoming a variety of ALK/EGFR associated drug resistant mutants in NSCLC.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2017, European journal of medicinal chemistry.

An overview of kinase downregulators and recent advances in discovery approaches

Qingsong Liu, Hai-zhen Wang, Hong Wu, 2021, Signal Transduction and Targeted Therapy.

Low dose of emetine as potential anti-SARS-CoV-2 virus therapy: preclinical in vitro inhibition and in vivo pharmacokinetic evidences

C. Liang, Liangdan Sun, Qingsong Liu, 2020, Molecular Biomedicine.

The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma.

Bandana Sharma, Wenchao Wang, Nathanael S Gray, 2012, Cancer cell.

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration

Ruben Dries, R. Palmer, B. Hallberg, 2021, Cell reports.

Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.

Qingsong Liu, Xiaofei Liang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Inhibition of the deubiquitinating enzyme USP47 as a novel targeted therapy for hematologic malignancies expressing mutant EZH2

W. Ni, J. Griffin, Q. Liu, 2022, Leukemia.

Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)

Qingsong Liu, C. Yun, Zhenquan Hu, 2016, Oncotarget.

Discovery of (R)-1-(3-(4-Amino-3-(3-chloro-4-(pyridin-2-ylmethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (CHMFL-EGFR-202) as a Novel Irreversible EGFR Mutant Kinase Inhibitor with a Distinct Binding Mode.

Jing Liu, Cheng Chen, Wei Wang, 2017, Journal of medicinal chemistry.

Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a Potent and Orally Available FLT3 Kinase Inhibitor for FLT3-ITD Positive Acute Myeloid Leukemia.

Qingsong Liu, Zheng Zhao, Hong Wu, 2015, Journal of medicinal chemistry.

Discovery of 1-(4-(4-Amino-3-(4-(2-morpholinoethoxy)phenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)phenyl)-3-(5-(tert-butyl)isoxazol-3-yl)urea (CHMFL-FLT3-213) as a Highly Potent Type II FLT3 Kinase Inhibitor Capable of Overcoming a Variety of FLT3 Kinase Mutants in FLT3-ITD Positive AML.

Zhenquan Hu, Q. Liu, Hong Wu, 2017, Journal of medicinal chemistry.

Repurposing cabozantinib to GISTs: Overcoming multiple imatinib-resistant cKIT mutations including gatekeeper and activation loop mutants in GISTs preclinical models.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2019, Cancer letters.

Axitinib overcomes multiple imatinib resistant cKIT mutations including the gatekeeper mutation T670I in gastrointestinal stromal tumors

Qingsong Liu, X. Liu, X. Xiao, 2019, Therapeutic advances in medical oncology.

Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode

Qingsong Liu, C. Yun, Hong Wu, 2017, Oncotarget.

Discovery of 2-(4-Chloro-3-(trifluoromethyl)phenyl)- N-(4-((6,7-dimethoxyquinolin-4-yl)oxy)phenyl)acetamide (CHMFL-KIT-64) as a Novel Orally Available Potent Inhibitor against Broad-Spectrum Mutants of c-KIT Kinase for Gastrointestinal Stromal Tumors.

Zhenquan Hu, Q. Liu, Cheng Chen, 2019, Journal of medicinal chemistry.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Q. Liu, Zong-ru Jiang, Cheng Chen, 2020, Acta Pharmacologica Sinica.

Pharmacologically inhibiting phosphoglycerate kinase 1 for glioma with NG52

Zong-ru Jiang, Cheng Chen, Ao-li Wang, 2020, Acta Pharmacologica Sinica.

Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies

Q. Liu, Hong Wu, Zong-ru Jiang, 2023, Signal Transduction and Targeted Therapy.

Discovery of ( E)- N1-(3-Fluorophenyl)- N3-(3-(2-(pyridin-2-yl)vinyl)-1 H-indazol-6-yl)malonamide (CHMFL-KIT-033) as a Novel c-KIT T670I Mutant Selective Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

X. Liu, Zhenquan Hu, Q. Liu, 2019, Journal of medicinal chemistry.

Targeting chaperon protein HSP70 as a novel therapeutic strategy for FLT3-ITD-positive acute myeloid leukemia

Qingsong Liu, Yinsheng Wang, E. Weisberg, 2021, Signal Transduction and Targeted Therapy.

Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a highly selective irreversible Bruton's tyrosine kinase (BTK) inhibitor.

Qingsong Liu, C. Yun, Zhenquan Hu, 2017, European journal of medicinal chemistry.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

A. Look, N. Gray, Qingsong Liu, 2013, ACS chemical biology.

Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation

N. Gray, Qingsong Liu, Jinhua Wang, 2016, Oncotarget.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Dopamine receptor D3 regulates endocytic sorting by a Prazosin-sensitive interaction with the coatomer COPI

T. Mitchison, U. Eggert, M. Coughlin, 2012, Proceedings of the National Academy of Sciences.

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.

X. Liu, Zhenquan Hu, Q. Liu, 2020, European journal of medicinal chemistry.

Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia.

Qingsong Liu, Cheng Chen, Ao-li Wang, 2020, Experimental cell research.

All-Trans Retinoic Acid Exerts Selective Anti-FLT3-ITD Acute myeloid leukemia Efficacy through Downregulating Chk1 Kinase.

Qingsong Liu, Zong-ru Jiang, Juan Liu, 2020, Cancer letters.

Discovery of a novel and highly selective CDK9 kinase inhibitor (JSH-009) with potent antitumor efficacy in preclinical acute myeloid leukemia models

Q. Liu, Hong Wu, Zong-ru Jiang, 2019, Investigational New Drugs.

CHMFL-26 is a highly potent irreversible HER2 inhibitor for use in the treatment of HER2-positive and HER2-mutant cancers

Qingsong Liu, Q. Liu, Hong Wu, 2022, Acta Pharmacologica Sinica.

Simultaneous inhibition of Vps34 kinase would enhance PI3Kδ inhibitor cytotoxicity in the B-cell malignancies

Qingsong Liu, J. Griffin, S. Fernandes, 2016, Oncotarget.

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Qingsong Liu, J. Griffin, S. Fernandes, 2016, OncoTarget.

Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.

Wenchao Wang, Wei Chen, Xinmiao Ji, 2016, Bioelectrochemistry.

Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway

Q. Liu, Hong Wu, Zong-ru Jiang, 2020, Acta Pharmacologica Sinica.

Nintedanib overcomes drug resistance from upregulation of FGFR signalling and imatinib‐induced KIT mutations in gastrointestinal stromal tumours

Qingsong Liu, Hong Wu, Zong-ru Jiang, 2022, Molecular oncology.

Discovery of N-((1-(4-(3-(3-((6,7-Dimethoxyquinolin-3-yl)oxy)phenyl)ureido)-2-(trifluoromethyl)phenyl)piperidin-4-yl)methyl)propionamide (CHMFL-KIT-8140) as a Highly Potent Type II Inhibitor Capable of Inhibiting the T670I "Gatekeeper" Mutant of cKIT Kinase.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Discovery of a highly potent pan-RAF inhibitor IHMT-RAF-128 for cancer treatment.

Q. Liu, Zong-ru Jiang, Juan Liu, 2023, European journal of pharmacology.

Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-nicotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL/KIT-155) as a Novel Highly Potent Type II ABL/KIT Dual Kinase Inhibitor with a Distinct Hinge Binding.

Qingsong Liu, Zhenquan Hu, Juan Liu, 2017, Journal of medicinal chemistry.

Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent

X. Liu, Q. Liu, Zong-ru Jiang, 2019, Acta pharmaceutica Sinica. B.

1 T moderate intensity static magnetic field affects Akt/mTOR pathway and increases the antitumor efficacy of mTOR inhibitors in CNE-2Z cells

Xingxing Yang, Zhiyuan Li, Wen-chao Wang, 2015 .

Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML

J. Griffin, E. Weisberg, Zheng Zhao, 2016, Oncotarget.

Discovery of a Highly Selective STK16 Kinase Inhibitor.

N. Gray, Qingsong Liu, Jinhua Wang, 2016, ACS chemical biology.

Discovery of N-(3-((1-Isonicotinoylpiperidin-4-yl)oxy)-4-methylphenyl)-3-(trifluoromethyl)benzamide (CHMFL-KIT-110) as a Selective, Potent, and Orally Available Type II c-KIT Kinase Inhibitor for Gastrointestinal Stromal Tumors (GISTs).

Qingsong Liu, Yuexiang Wang, Zhenquan Hu, 2016, Journal of medicinal chemistry.

Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitor (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML)

Zhenquan Hu, Q. Liu, Hong Wu, 2019, Cancer biology & therapy.

Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

Q. Liu, Chen Hu, F. Zou, 2023, Acta pharmaceutica Sinica. B.

Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus

Q. Liu, Chen Hu, F. Zou, 2023, Signal Transduction and Targeted Therapy.

Structure-based discovery of IHMT-IDH1-053 as a potent irreversible IDH1 mutant selective inhibitor.

Q. Liu, Chen Hu, F. Zou, 2023, European journal of medicinal chemistry.

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model

N. Gray, Qingsong Liu, Wei Wei, 2017, Scientific Reports.

Moderate intensity static magnetic fields affect mitotic spindles and increase the antitumor efficacy of 5-FU and Taxol.

Qingsong Liu, Zhiyuan Li, Wen-chao Wang, 2016, Bioelectrochemistry.

Discovery of a selective irreversible BMX inhibitor for prostate cancer.

N. Gray, Qingsong Liu, W. Hur, 2013, ACS chemical biology.

Qingsong Liu, Zhenquan Hu, Hong Wu, 2016, Journal of medicinal chemistry.

Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells

N. Gray, Qingsong Liu, Jinhua Wang, 2015, Oncotarget.

Insensitivity of oncogenic EGFR R776L mutation to EGFR inhibitors in lung cancer.

Chen Hu, Wen-chao Wang, Hongwei Yu, 2024, Lung cancer.

Xiaofei Liang, Zhenquan Hu, Q. Liu, 2018, Journal of medicinal chemistry.

Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia

X. Liu, M. Eck, J. Griffin, 2016, Leukemia.